Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2022 · 10-Q
Revenue—
Net Income-$2.48M-$2.48MN/M vs Q3 2021 EPS Diluted-$1.46-$1.46N/M vs Q3 2021 Operating Income-$5,656,849N/M Operating Cash Flowderived-$4,550,468N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,569,042— ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end